Triamcinolon acetonid

Triamcinolon acetonid
(IUPAC) ime
	(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-; 4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl- 4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho [2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
Klinički podaci
Identifikatori
CAS broj	76-25-5
ATC kod	H02AB08
PubChem	6436
Hemijski podaci
Formula	C24H31FO6
Mol. masa	434.497 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1 ; Key: YNDXUCZADRHECN-JNQJZLCISA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Triamcinolon acetonid je potentniji tip Triamcinolona. On je oko 8 puta efektivniji od prednizona. Triamcinolon acetonid ne treba da se koristi u slučajevima tuberkuloze, ili netretiranih fungalnih, bakterijskih, viralnih (npr. herpes)^[3]^[4] infekcija bez lekarskog pregleda. Veoma mali broj nuspojava je uočen u toku kliničkih istraživanja.^[5]^[6] Negde 5% pacijenata je imalo upaljeno grlo, i 2% je imalo problema sa pojačanim kašljem. Predoziranje je malo verovatno, i efekti takvog jednog predoziranja su uglavnom ograničeni na gastrointestinalne probleme. Maksimalna doza za odrasle i decu (uzrasta 6-12) je 220 mg dnevno.

Serija injekcija sa triamcinolon acetonidom ili nekim drugim kortikosteroidom može smanjiti rast tkiva ožiljaka na mestima hirurškog zaseka.^[7]

Triamcinolon acetonid se isto tako koristi u veterinarskoj medicini^[8] kao sastojak topičkih masti.

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Smith JF (1963). „The clinical use of triamcinolone acetonide in the treatment of herpes simplex of the oral mucous membranes”. Oral Surg Oral Med Oral Pathol 16: 150-3. PMID 13989463.
↑ Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). „Chapter 59. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and actions of adrenocortical hormones”. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 izd.). New York: McGraw-Hill. ISBN 0-07-142280-3.
↑ Diabetic Retinopathy Clinical Research Network (2008). „A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema”. Ophthalmology 115 (9): 1447-9. PMID 18662829.
↑ Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005). „Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial”. Invest Ophthalmol Vis Sci 46 (10): 3845-9.
↑ Hochman B, Locali RF, Matsuoka PK, Ferreira LM (2008). „Intralesional Triamcinolone Acetonide for Keloid Treatment: A Systematic Review”. J. Aesthetic Plastic Surgery 32 (4): 705-709. DOI:10.1007/s00266-008-9152-8.
↑ „NADA 138-869 Triamcinolone Acetonide Injection, 2 mg/ml & 6 mg/ml - original approval”.

Literatura uredi

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[herpes-3] Smith JF (1963). „The clinical use of triamcinolone acetonide in the treatment of herpes simplex of the oral mucous membranes”. Oral Surg Oral Med Oral Pathol 16: 150-3. PMID 13989463.

[Goodman_Gilman-4] Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). „Chapter 59. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and actions of adrenocortical hormones”. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 izd.). New York: McGraw-Hill. ISBN 0-07-142280-3.

[5] Diabetic Retinopathy Clinical Research Network (2008). „A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema”. Ophthalmology 115 (9): 1447-9. PMID 18662829.

[Bonini-Filho-6] Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005). „Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial”. Invest Ophthalmol Vis Sci 46 (10): 3845-9.

[Hochman-7] Hochman B, Locali RF, Matsuoka PK, Ferreira LM (2008). „Intralesional Triamcinolone Acetonide for Keloid Treatment: A Systematic Review”. J. Aesthetic Plastic Surgery 32 (4): 705-709. DOI:10.1007/s00266-008-9152-8.

[Animal_&_Veterinary-8] „NADA 138-869 Triamcinolone Acetonide Injection, 2 mg/ml & 6 mg/ml - original approval”.

[3]

[4]

[5]

[6]

[1]

[2]

[7]

[8]